Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial - PubMed

For the Chinese translation of the abstract see Supplementary Materials section.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov